Dextenza Approval Status
- FDA approved: No
- Brand name: Dextenza
- Generic name: dexamethasone
- Dosage form: Intracanalicular Depot
- Company: Ocular Therapeutix, Inc.
- Treatment for: Postoperative Ocular Inflammation
Dextenza (dexamethasone) is an investigational intracanalicular depot corticosteroid formulation designed to deliver sustained release dexamethasone to the ocular surface for up to 30 days after ophthalmic surgery for the treatment of post-surgical ocular inflammation and pain.
Development Status and FDA Approval Process for Dextenza
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
